Is There Any Connection Between the Presence of Kidney Stones in Primary Hyperparathyroidism and the Location of an Underlying Adenoma?

Abstract

The majority of the patients with primary hyperparathyroidism (pHPT) recurrently produce kidney stones, while the rest have other clinical manifestations. The aim of this study was to examine the possibility of an association between the presence of kidney stones and the location of an underlying adenoma. This was a retrospective evaluation of the records of 91 patients (10 males, 81 females, mean age: 61.9 years [20 - 70 yrs]) operated for primary hyperparathyroidism between 1995 and 2000. One patient was excluded due to carcinoma. Kidney stones were found in 55 cases and other clinical symptoms in 35 cases. In 50 of the 55 patients (91 %) with kidney stones, the adenoma was located in the left inferior parathyroid gland (χ² = 67.5, p < 0.00,001), while in 24 of the 35 patients (69 %) without kidney stones, the adenoma was in the right inferior parathyroid gland (χ² = 43.9, p < 0.0001). These results suggest that the location of the adenoma may influence the presence of kidney stones in pHPT. It is proposed that the biologic effects of parathyroid hormone could differ depending on which of the four parathyroid glands it was secreted in, or the four glands may produce different biologically active fragments.

Primary hyperparathyroidism - kidney stones - location of adenoma

References

• 1 Alvarez-Arroyo M V, Traba M L, Rapado A, De La Piedra C. Role of citric acid in primary hyperparathyroidism with renal lithiasis.  Urol Res. 1992;  20 88-90
• 2 Ander S, Johansson K, Smeds S. Blood supply and parathyroid hormone secretion in pathological parathyroid glands.  World J Surg. 1996;  20 598-601
• 3 Aurbach G D, Marx S J, Spiegel A M. Parathyroid hormone, calcitonin, and the calciferols. Wilson JD, Foster DW Textbook of Endocrinology. 8th ed. Philadelphia; WB Saunders Company 1992: 1397-1477
• 4 Chen Z, Xu P, Barbier J R, Willick G, Ni F. Solution structure of the osteogenic 1 - 31 fragment of human parathyroid hormone.  Biochemistry. 2000;  39 12766-12777
• 5 Chou F F, Wang P W, Sheen-Chen S M. Preoperative localization of parathyroid glands in primary hyperparathyroidism.  Eur J Surg. 1997;  163 889-895
• 6 D'Angelo A, Calo L, Cantaro S. Calciotropic hormones and nephrolithiasis.  Miner Electrolyte Metab. 1997;  23 269-272
• 7 Dong-Ming S, Ellis S, Napier A, Lee K, Manley N R. Hoxa 3 and Pax1 regulate epithelial cell death and proliferation during thymus and parathyroid organogenesis.  Dev Biol. 2001;  236 316-329
• 8 Frokjaer V G, Mollerup C L. Primary hyperparathyroidism: renal calcium excretion in patients with and without renal stone disease before and after parathyroidectomy.  World J Surg. 2002;  26 532-535
• 9 Hirasawa T, Nakamura T, Mizushima A, Morita M, Ezawa I, Miyakawa H, Kudo Y. Adverse effects of an active fragment of parathyroid hormone on rat hippocampal organotypic cultures.  Br J Pharmacol. 2000;  129 21-28
• 10 Irvin G L, Carneiro D M. Management changes in primary hyperparathyroidism.  JAMA. 2000;  284 934-936
• 11 Khan A, Bilezikian J. Primary hyperparathyroidism: path physiology and impact on bone.  Can Med Assoc J. 2001;  163 184-187
• 12 Koslin D B, Adams P, Everts E, Cohen J. Preoperative evaluation of patients with primary hyperparathyroidism: role of high resolution ultrasound.  Laryngoscope. 1997;  107 1249-1253
• 13 Le H N, Norton J A. Surgical management of hyperparathyroidism. DeGroot LJ, Jameson JL Endocrinology. 4th ed. Philadelphia; Saunders Company 2001: 111-113
• 14 Lesser T, Bartel M. Primary hyperparathyroidism. Pathogenesis diagnosis-therapy.  Zentralbl Chir. 1992;  117 41-49
• 15 Lumachi F, Zucchetta P, Varotto S, Polistina F, Favia G, D'Amico D. Noninvasive localization procedures in ectopic hyperfunctioning parathyroid tumors.  Endocr-Relat Cancer. 1999;  6 123-125
• 16 Luts L, Bergenfelz A, Aluments J, Sundler F. Peptide-containing nerve fibres in normal human parathyroid glands and in human parathyroid adenomas.  Eur J Endocrinol. 1995;  133 543-551
• 17 Manley N R, Capecchi M. Hox group 3 para logs regulate the development and migration of the thymus, thyroid and parathyroid glands.  Dev Biol. 1998;  195 1-15
• 18 Marx S J. Medical progress: hyper parathyroid and hypo parathyroid disorders.  N Engl J Med. 2000;  343 1863-1875
• 19 Marx U C, Adermann K, Bayer P, Frossmann W G, Rosch P. Solution structures of human parathyroid hormone fragments hPTH(1 - 34) and hPTH(1 - 39) and bovine parathyroid hormone fragment bPTH(1 - 37).  Biochem Biophys Res Commun. 2000;  267 213-220
• 20 Melliere D, Berrahal D, Perlemuter L, Hindie E, Simon D. Primary hyperparathyroidism. Relationships of symptoms to age, sex, calcemia, anatomical lesions and weight of the glands.  Presse Med. 1995;  24 1889-1993
• 21 Melton L J. Epidemiology of primary hyperparathyroidism.  J Bone Miner Res. 1991;  6 25-30
• 22 Moore K L, Persaud T VN. The Developing Human (Clinically Oriented Embryology). 5th ed. New York; W. B. Saunders Company 2000: 118
• 23 Nobori M, Saiki S, Tanaka N, Harihara Y, Shindo S, Fujimoto Y. Blood supply of parathyroid gland from the superior thyroid artery.  Source Surgery. 1994;  115 417-423
• 24 Okada Y, Mizutani Z, Takeuchi H, Shigeno C, Konishi J, Yoshida O. Preoperative imaging for parathyroid localization in primary hyperparathyroidism.  Int J Urol. 1997;  4 338-442
• 25 Onyja J E, Miles R R, Yang X, Halladay D L, Hale J, Glasebrook A. In vivo demonstration that human parathyroid hormone 1 - 38 inhibits the expression of osteroprotegerin in bone with the kinetics of an immediate early gene.  J Bone Miner Res. 2000;  15 863-871
• 26 Rauth J D, Session R B, Shupe S C, Ziessmann H A. Comparison of Tc-99 m MIBI and TI-201/Tc-99 m pertechnetate for diagnosis of primary hyperparathyroidism.  Clin Nucl Med. 1996;  21 602-608
• 27 Roth H J. Elecsys parathyroid hormone (PTH) not detecting large PTH fragment hPTH (7 - 84).  Clin Lab. 2000;  46 295-299
• 28 Rubello D, Saladini G, Casara D, Borsato N, Toniato A, Piotto A, Bernante P, Pelizzo M R. Parathyroid imaging with pertechnetate plus perchlorate/MIBI subtraction scintigraphy: a fast and effective technique.  Clin Nucl Med. 2000;  25 527-531
• 29 Shimizu M, Potts J T, Gardella T J. Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor.  J Biol Chem. 2000;  275 21836-21843
• 30 Silverberg S J, Shane E, Jacobs T P, Siris E, Bilezikian J P. A 10-year prospective study of primary hyperparathyroidism with and without parathyroid surgery.  N Engl J Med. 1999;  341 1249-1255
• 31 Soreide J A, Heerden J A, Grant C S, Lo C Y, Ilstrup D M. Characteristics of patients surgically treated for primary hyperparathyroidism with and without renal stones.  Surgery. 1996;  120 1033-1038
• 32 Thompson N W, Eckhauser F, Harness J. Anatomy of primary hyperparathyroidism.  Surgery. 1982;  92 814-827
• 33 Walgenbach S, Junginger T. Result of bilateral surgical technique in primary hyperparathyroidism.  Zentralbl Chir. 2001;  126 254-260
• 34 Wermers R A, Khosla S, Atkinson E J, Hodgson S F, Fallon W M, Melton III L J. The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965 - 1992.  Ann Int Med. 1997;  126 433-440
• 35 Whitfield J F, Morley P, Willick G E, Isaacs R J, MacLean S, Ross V, Barbier J R, Divieti P, Bringhurst F R. Lactam formation increases receptor binding, adenylyl cyclase stimulation and bone growth stimulation by human parathyroid hormone (hPTH) (1 - 28)NH2.  J Bone Miner Res. 2000;  15 964-970
• 36 Williams J G, Wheeler M H, Aston J P, Brown R C, Woodhead J. The relationship between adenoma weight and intact (1 - 84) parathyroid hormone level in primary hyperparathyroidism.  Am J Surg. 1992;  163 301-304
• 37 Yasudo I. Molecular pathogenesis of tumor genesis in sporadic parathyroid adenomas.  J Bone Miner Res. 2002;  20 190-195